5:48 PM
 | 
Oct 22, 2013
 |  BC Extra  |  Financial News

Novartis raises 2013 guidance on delayed generic Diovan competition

Novartis AG (NYSE:NVS; SIX:NOVN) again raised its 2013 sales guidance based on the continued delay of generic competition in the U.S. for hypertension drug Diovan...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >